ArticleBMC complementary medicine and therapies2025
Geniposide alleviates kidney fibrosis by targeting STAT3-HK2-mediated glycolysis.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactate-Mediated Lysine Lactylation in Renal Fibrosis: Current Progress and Challenges.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundGeniposide (GP), which is extracted from the traditional Chinese herb Gardenia jasminoides, has extensive pharmacological effects. Recently, studies have shown its protective effects on kidney diseases. However, whether GP can alleviate unilateral ureteral obstruction (UUO)-induced renal interstitial fibrosis is unknown. In addition, its potential protective mechanism against kidney fibrosis is worthy of further study. We investigated the effect of GP on renal interstitial fibrosis induced by UUO in vivo and on HK-2 cells treated with transforming growth factor β1 (TGF-β1) in vitro and explored the underlying mechanisms involved. MATERIALS AND
methodsA UUO model was constructed, and the mice were treated with GP (50 mg/kg/day) for 10 days. The kidney injury score was used to evaluate the degree of kidney injury based on HE staining, and Masson staining and immunohistochemistry were used to evaluate kidney fibrosis. High-throughput sequencing analysis of animal samples was subsequently conducted, and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional and pathway enrichment analyses were subsequently performed to determine the possible mechanism, which were subsequently validated in vitro and in vivo. Western blotting was used to detect the signal transducer and activator of transcription 3 (STAT3)/hexokinase 2 (HK2) pathway, and molecular docking analysis was used to evaluate the binding ability of GP and STAT3. STAT3 was also overexpressed in HK-2 cells.
resultsGP alleviated renal fibrosis, regulated the glycolysis-related protein HK2 and inhibited glycolysis by binding to STAT3. In vitro experiments revealed that GP regulated glycolysis-related proteins and prevented cell epithelial-to-mesenchymal transition (EMT) during TGF-β1 treatment in HK-2 cells. Furthermore, the phosphorylation of STAT3 was drastically reduced in response to GP stimulation, leading to attenuated STAT3 nuclear translocation. Molecular docking analysis revealed a stable conformation between GP and STAT3 at Tyr705. The effects of GP were blocked by overexpression of STAT3.
conclusionOur results showed that GP protected against renal fibrosis, possibly through inhibiting STAT3/HK2 signaling-mediated glucose metabolism in UUO mouse kidneys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.